Population Estimates of Sickle Cell Disease in the U.S.

American Journal of Preventive Medicine

Volumn 38, Issue 4 SUPPL., 2010, Pages

  Hassell, Kathryn L ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AFRICAN AMERICAN; AGE DISTRIBUTION; AGED; CHILD; COHORT ANALYSIS; EUROPEAN AMERICAN; FEMALE; GEOGRAPHIC DISTRIBUTION; HEALTH SURVEY; HISPANIC; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PREVALENCE; RACE DIFFERENCE; REVIEW; SCHOOL CHILD; SICKLE CELL ANEMIA; SURVIVAL TIME; UNITED STATES;

ADULT; AFRICAN AMERICANS; AGE FACTORS; ANEMIA, SICKLE CELL; CENSUSES; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); COHORT STUDIES; COST OF ILLNESS; HISPANIC AMERICANS; HUMANS; INFANT, NEWBORN; MORTALITY; NEONATAL SCREENING; POPULATION SURVEILLANCE; PREVALENCE; SEX FACTORS; UNITED STATES;

EID: 77949482609     PISSN: 07493797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amepre.2009.12.022     Document Type: Review

References (21)

1. Lukens J.N. Sickle cell disease. Dis Mon 27 (1981) 1-56
2. Sickle Cell Disease Guideline Panel. Sickle cell disease: screening, diagnosis, management, and counseling in newborns and infants. Clinical Practice Guideline No. 6. AHCPR Pub. No. 93 0562 (1993), Agency for Health Care Policy and Research, Public Health Service, USDHHS, Rockville MD
3. CDC. Health care professionals: data & statistics. www.cdc.gov/ncbddd/sicklecell/hcp_data.htm
4. National Heart Lung and Blood Institute. Who is at risk for sickle cell anemia?. www.nhlbi.nih.gov/health/dci/Diseases/Sca/SCA_WhoIsAtRisk.html
5. Strouse J.J., Jordan L.C., Lanzkron S., and Casella J.F. The excess burden of stroke in hospitalized adults with sickle cell disease. Am J Hematol 84 9 (2009) 548-552
6. Kauf T.L., Coates T.D., Huazhi L., Mody-Patel N., and Hartzema A.G. The cost of health care for children and adults with sickle cell disease. Am J Hematol 84 (2009) 323-327
7. U.S. Census Bureau. www.census.gov
8. Therrell B.L., and Hannon W.H. National evaluation of U.S. newborn screening system components. MRDD Research Reviews 12 (2006) 236-245
9. Lorey F.W., Arnopp J., and Cunningham G.C. Distribution of hemoglobinopathy variants by ethnicity in a multiethnic state. Genetic Epidemiol 13 (1996) 501-512
10. Michlitsch J., Azimi M., Hoppe C., et al. Newborn screening for hemoglobinopathies in California. Pediatr Blood Cancer 52 (2009) 486-490
11. National Newborn Screening Information System. www2.uthscsa.edu/nnsis/
12. Platt O.S., Brambilla D.J., Rosse W.F., et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. NEJM 330 (1994) 1639-1644
13. Quinn C.T., Rogers Z.R., and Buchanan G.R. Survival of children with sickle cell disease. Blood 103 (2004) 4023-4027
14. Telfer P., Coen P., Chakravorty S., et al. Clinical outcomes in children with sickle cell disease living in England: a neonatal cohort in East London. Haematologica 92 (2007) 905-912
15. King L., Fraser R., Forbes M., Grindley M., Ali S., and Reid M. Newborn sickle cell disease screening: the Jamaican experience (1995-2006). J Med Screen 14 (2007) 117-122
16. Wierenga K.H., Hambleton I.R., and Lewis N.A. Survival estimates for patients with homozygous sickle-cell disease in Jamaica: a clinic-based population study. Lancet 357 9257 (2001) 680-683
17. Serjeant G.R., Serjeant B.E., Mason K.P., Hambleton I.R., Fisher C., and Higgs D.R. The changing face of homozygous sickle cell disease: 102 patients over 60 years. Int J Lab Hem 31 (2009) 585-596
18. CDC, National Center for Health Statistics. Compressed mortality file 1999-2006. CDC WONDER On-line Database, compiled from compressed mortality file 1999-2006 series 20 No. 2L (2009). wonder.cdc.gov/cmf-icd10.html
19. Gaston M.H., Verter J.I., Woods G., et al. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. NEJM 314 (1986) 1593-1599
20. Steinberg M.H., Barton F., Castro O., et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA 289 (2003) 1645-1651
21. Ashley-Koch A., Yang Q., and Olney R.S. Sickle hemoglobin (HbS) allele and sickle cell disease: a HuGE review. Am J Epidemiol 151 (2000) 839-845